Buprenorphine-treated patients (n = 51) | ||||
---|---|---|---|---|
Predictors in the reduced model | Step1 Beta (t-test)a,b | Step2 Beta (t-test) | Step3 Beta (t-test) | Step4 Beta (t-test) |
Drug treatment variables | Â | Â | Â | Â |
BZD treatment (yes vs. no) | .34 | .36 | .37 | .38 |
t(49) = 2.51 | t(48) = 2.64 | t(47) = 2.60 | t(46) = 2.60 | |
p = 0.015* | p = 0.011* | p = 0.012* | p = 0.013* | |
Buprenorphine dose (high vs. low)c | Â | -.16 | -.17 | -.19 |
The number of psychoactive drugs, other than opioid or BZD (high vs. low)d | Â | Â | .05 | .05 |
Duration of OST (long vs. short)e | Â | Â | Â | -.05 |
R2 (adjusted) | .096 | .103 | .084 | .069 |
Model (ANOVA)a | F(1,49)= 6.29 | F(2,48)= 3.88 | F(3,47) = 2.58 | p = 0.12 |
p = 0.015* | p = 0.027* | p = 0.065# | Â | |
Change (ANOVA)a | Â | p = 0.24 | p = 0.76 | p = 0.71 |
Methadone-treated patients (n = 51) | ||||
Predictors in the reduced model | Step1 Beta ( t -test) a,b | Step2 Beta ( t -test) | Step3 f Beta ( t -test) | Â |
Drug treatment variables | Â | Â | Â | |
The number of psychoactive drugs, other than opioid or BZD (high vs. low) | .27 # | .30 * | . 31 * | |
t(49) = 1.92 | t(48) = 2.21 | t(47) = 2.09 | ||
p = 0.060# | p = 0.032* | p = 0.042* | ||
Methadone dose BZD treatment (yes vs. no) | Â | .26 # | .26 # | |
 | t(48) = 1.88 | t(47) = 1.86 | ||
 | p = 0.066# | p = 0.069# | ||
 |  | -.02 | ||
R2 (adjusted) | .051 | .098 | .073 | |
Model (ANOVA)a | F(1,49) = 3.71 | F(2,48) = 3.72 | F(3,47) = 2.43 | |
p = 0.060# | p = 0.032* | p = 0.077 # | ||
Change (ANOVA)a | Â | 0.066 # | 0.90 |